Ginkgo and bayer sign definitive agreement to build agricultural biologicals r&d platform capabilities

Ginkgo to acquire bayer's 175,000-square-foot biologics r&d center and enter into a new multi-year platform collaboration with bayer to advance several agricultural biological programs boston , july 25, 2022 /prnewswire/ -- ginkgo bioworks (nyse: dna), the leading horizontal platform for cell programming, today announced the signing of a definitive agreement for the previously announced transaction with bayer to expand ginkgo's platform capabilities in agricultural biologicals. these capabilities will be built pursuant to a transaction in which ginkgo will acquire bayer's 175,000-square-foot west sacramento biologics research & development site, team, and internal discovery and lead optimization platform for approximately $83.0 million in consideration.
DNA Ratings Summary
DNA Quant Ranking